NCT00708422

Effects of Travatan Z and Xalatan on Ocular Surface Health

Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and Xalatan®

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 231 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this randomized, double-masked, parallel-group, multicenter study is to evaluate ocular surface effects after the administration of travoprost with SofZia® preservative system or Xalatan once daily for 12 weeks.

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)	Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
DRUG	Latanoprost ophthalmic solution 0.005% (XALATAN®)	Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-08-01
• Completion: 2009-08-01
• First posted: 2008-07-02
• Last updated: 2012-04-23
• Results posted: 2012-04-23